Abstract
To the Editor: Apremilast is an oral phosphodiesterase-4 inhibitor that is approved for the treatment of psoriasis.1 It was shown to be effective in controlling progression of vitiligo,2 but another study found that apremilast does not bring any additional benefit to narrowband ultraviolet B light (NB-UVB) phototherapy.3 That study, however, included a low proportion of skin phototypes (SPTs) IV to VI and lacked the advantage of a bilateral comparison study design. Our study evaluated the efficacy of apremilast plus NB-UVB phototherapy compared with NB-UVB phototherapy alone in patients with SPTs IV to VI with generalized vitiligo (≥20% body surface area).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
